Adjuvant Therapy
40
14
19
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
2.5%
1 terminated out of 40 trials
75.0%
-11.6% vs benchmark
15%
6 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (40)
Reduce Sedentary Behavior During Cancer Treatment - the RedSedCan Study
Chemotherapy Exemption in Elderly Women With Node-Positive ER+/HER2- Breast Cancer
PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery
Adjuvant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immunochemotherapy and Surgery in High-Risk NSCLC
Estimation and Prediction of Individual Benefit From Postoperative Adjuvant Transcatheter Arterial Chemoembolization For Patients With Hepatocellular Carcinoma
A Non-interventional, Real-world Study on the Adjuvant Treatment of Chinese EGFR-positive Stage IA NSCLC Patients With High-risk Factors Using Third-generation EGFR-TKIs.
Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma
A Prospective, Multicenter, Phase II Clinical Study of Postoperative Chemotherapy Combined With QL1706 for High-risk Triple-negative Breast Cancer.
Breast Cancer RElapsed in Patients Treated With Adjuvant CDK4/6 Inhibitors:
An Antibody-armored Dendritic Cell in Patients With Solid Tumors
A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical Cancer
Adjuvant Anti-PD-1 Therapy in Resected Hepatocellular Carcinoma
CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)
A Retrospective Observational Study of Patients With Early-stage HER2-positive Breast Cancer, Treated With Neratinib
Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients
Pucotenlimab Combined With Chemotherapy as Perioperative Treatment for Locally Advanced Gastroesophageal Junction Carcinoma
Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer
Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast Cancer
Prognostic Impact of Adjuvant Therapy in Primary Hepatic Sarcomatoid Carcinoma
The Significance and Indications of Surgery for Synchronous Liver Metastatic Pancreatic Cancer